Search

Your search keyword '"niraparib"' showing total 183 results
Start Over Descriptor "niraparib" Publication Type News
183 results on '"niraparib"'

1. GlaxoSmithKline (LSE: GSK)

Subjects
United States. Food and Drug Administration, Pfizer Inc. -- Joint ventures, GlaxoSmithKline PLC -- Joint ventures, Niraparib, Rilpivirine, Health care industry -- Joint ventures, Dolutegravir, Pembrolizumab, Pharmaceutical industry -- Joint ventures, Belimumab, Drugstores, Pharmacy, Health care industry, Company joint venture, Business, international, Seretide (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Tivicay (Medication), Nucala (Medication), Pediarix (Vaccine), Benlysta (Medication), Infanrix (Medication), Dovato (Medication), Advair Diskus (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

2. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline pic was formed in 2000 as a result of [...]

Published
2019

3. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., GlaxoSmithKline PLC, Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

4. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., GlaxoSmithKline PLC, Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

5. GlaxoSmithKline (LSE: GSK)

Subjects
Pfizer Inc., GlaxoSmithKline PLC, Niraparib, Rilpivirine, Health care industry, Bevacizumab, Dolutegravir, Pharmaceutical industry, Drugstores, Pharmacy, Health care industry, Business, international, Seretide (Medication), Nucala (Medication), Benlysta (Medication), Dovato (Medication), Trelegy Ellipta (Medication), Boostrix (Vaccine), Juluca (Medication), Zejula (Medication), Advair Diskus (Medication), Tivicay (Medication), Breo Ellipta (Medication)
Abstract

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc was formed in 2000 as a result of [...]

Published
2019

7. Rammeaftale Om Kb Af Zejula (niraparib) 2020 - In1.603.a (denmark-copenhagen: Pharmaceutical Products)

Subjects
GlaxoSmithKline Pharma A/S -- Officials and employees, Niraparib, Pharmaceutical industry -- Officials and employees, Business, international, Zejula (Medication)
Abstract

Contract award notice: Rammeaftale om kb af zejula (niraparib) 2020 - in1.603.a (denmark-copenhagen: Pharmaceutical products) Formlet med rammeaftalen er at kunne forsyne sygehusapotekerne hos Amgros~ interessenter med lgemidlet Zejula (niraparib). [...]

Published
2020

8. European Commission Approves Niraparib as Maintenance Treatment in Advanced Ovarian Cancer

Subjects
United States. Food and Drug Administration, Niraparib, Chemotherapy, Ovarian cancer -- Drug therapy, Business, international, Law, European Union. European Commission
Abstract

The European Commission has approved niraparib (Zejula; GSK), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as first-line monotherapy maintenance treatment for adult patients with advanced epithelial (FIGO Stages III [...]

Published
2020

9. Onxeo Announces Enrollment of First Patient in Phase Ib|II Study Revocan

Subjects
Cancer treatment, Niraparib, Medical research, Ovarian cancer -- Care and treatment, General interest, News, opinion and commentary
Abstract

PARIS: Onxeo S.A. has issued the following news release: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ('Onxeo' or 'the Company'), a clinical-stage biotechnology company specializing in the development of innovative [...]

Published
2020

10. Onxeo Announces Enrollment of First Patient in Phase Ib|II Study Revocan

Subjects
Cancer treatment, DNA damage, Niraparib, Medical research, Carboplatin, Ovarian cancer -- Care and treatment -- Development and progression, Business, international, Law
Abstract

(GlobeNewswire) - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (Onxeo or the Company), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), [...]

Published
2020

11. Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

Subjects
Cancer treatment, DNA damage, Niraparib, Medical research, Carboplatin, Ovarian cancer -- Care and treatment -- Development and progression, Banking, finance and accounting industries, Business
Abstract

PARIS, Oct 21, 2020 (GLOBE NEWSWIRE via COMTEX) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ('Onxeo' or 'the Company'), a clinical-stage biotechnology company specializing in the development of innovative [...]

Published
2020

12. For women with ovarian cancer, early communication is key

Subjects
Niraparib, Women, Ovarian cancer, News, opinion and commentary, Sports and fitness, Zejula (Medication)
Abstract

- At first thought, it would appear that Cherie, age 50 from Chicago, Illinois, and Leanne, age 62 from White Plains, New York, don't have much in common. Cherie enjoys [...]

Published
2020

13. GSKs Zejula and AZs Lynparza leap toward broader EU approval

Subjects
Niraparib, Bevacizumab, Ovarian cancer, Business, international, Law, Zejula (Medication), Lynparza (Medication)
Abstract

GlaxoSmithKlines Zejula and AstraZenecas Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agencys (EMA) Committee for Medicinal Products for Human [...]

Published
2020

14. Positive EU Committee Opinion For GlaxoSmithKline's Zejula

Subjects
GlaxoSmithKline PLC, Niraparib, Chemotherapy, Ovarian cancer, General interest, News, opinion and commentary, Zejula (Medication)
Abstract

London: GlaxoSmithKline PLC has issued the following press release: GlaxoSmithKline PLC on Friday reported that a European Medicines Agency committee has adopted a positive opinion on its cancer drug Zejula. [...]

Published
2020

15. 61|971|2020 Medicine Niraparib 100 Mg Capsule

Subjects
Niraparib, Business, international
Abstract

Contract awarded for 61/971/2020 medicine niraparib 100 mg capsule Date of conclusion of the contract: 21-02-2020 Contract price: 68. 625,50 Deadline: 314 days Place of execution - Country, District, Municipality: [...]

Published
2020

16. GSK receives CHMP positive opinion recommending approval of Zejula (niraparib) as first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer

Subjects
Niraparib, Chemotherapy, Ovarian cancer -- Care and treatment, Business, Business, international, Zejula (Medication)
Abstract

M2 PRESSWIRE-September 18, 2020-: GSK receives CHMP positive opinion recommending approval of Zejula (niraparib) as first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer (C)1994-2020 M2 COMMUNICATIONS RDATE:18092020 [...]

Published
2020

19. Takeda showcases ovarian cancer drug Zejulas widened indication, efficacy

Subjects
Takeda Pharmaceutical Company Ltd., Cancer genetics -- Drug therapy, Niraparib, Disease susceptibility -- Drug therapy, Pharmaceutical industry, Ovarian cancer -- Drug therapy, Business, international, Law, Zejula (Medication)
Abstract

Takeda Pharmaceuticals Korea held an online conference Thursday to highlight expanded indication for its ovarian cancer treatment Zejula (ingredient: niraparib) as the first-line maintenance and explained the clinical efficacy. Zejula [...]

Published
2020

20. Zai Lab Announces NMPA Approval of ZEJULA (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China

Subjects
Zai Lab Ltd., Niraparib, Chemotherapy, Pharmaceutical industry, Drug approval, Ovarian cancer -- Drug therapy -- Development and progression, Business, international, Law, Zejula (Medication)
Abstract

(GlobeNewswire) - Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its supplemental New Drug Application [...]

Published
2020

21. Zai Lab Announces NMPA Approval of ZEJULA(R) (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China

Subjects
Zai Lab Ltd., Cancer treatment, Niraparib, Pharmaceutical industry, Drug approval, Ovarian cancer -- Drug therapy -- Development and progression, Banking, finance and accounting industries, Business, Zejula (Medication)
Abstract

SHANGHAI and SAN FRANCISCO, Sep 10, 2020 (GLOBE NEWSWIRE via COMTEX) -- - ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line and recurrent [...]

Published
2020

22. FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US

Subjects
United States. Food and Drug Administration, GlaxoSmithKline PLC, Niraparib, Rilpivirine, Respiratory system agents, Pharmaceutical industry, Drug approval, Asthma -- Drug therapy, Vilanterol, Business, Business, international, Trelegy Ellipta (Medication)
Abstract

M2 PRESSWIRE-September 10, 2020-: FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US (C)1994-2020 M2 COMMUNICATIONS [...]

Published
2020

23. FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

Subjects
United States. Food and Drug Administration, GlaxoSmithKline PLC, Niraparib, Rilpivirine, Respiratory system agents, Drug approval, Asthma -- Drug therapy, Vilanterol, Business, Business, international, Trelegy Ellipta (Medication)
Abstract

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm LONDON & BURLINGAME, Calif. -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: [...]

Published
2020

24. Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020

Subjects
Zai Lab Ltd., Clinical trials, Niraparib, Ovarian cancer, Business, international, Law
Abstract

(GlobeNewswire) - Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data from the NORA Phase 3 study of niraparib have been [...]

Published
2020

25. Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020

Subjects
Zai Lab Ltd., Clinical trials, Niraparib, Pharmaceutical industry, Ovarian cancer, Banking, finance and accounting industries, Business
Abstract

SHANGHAI and SAN FRANCISCO, Sep 03, 2020 (GLOBE NEWSWIRE via COMTEX) -- Zai Lab Limited ('Zai Lab') (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data [...]

Published
2020

26. ASCO Releases New Guidelines on PARP Inhibitor Use for Management of Ovarian Cancer

Subjects
Evidence-based medicine, Niraparib, Bevacizumab, Olaparib, Ovarian cancer, Business, international, Law
Abstract

The American Society for Clinical Oncology (ASCO) published new guidelines on the use of PARP inhibitors in the management of ovarian cancer.1 The purpose of this guideline is to provide [...]

Published
2020

27. Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs

Subjects
Vice presidents (Organizations), Fidaxomicin, Daptomycin, Niraparib, Business, international, Law
Abstract

(GlobeNewswire) - Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical [...]

Published
2020

28. Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs

Subjects
Vice presidents (Organizations), Fidaxomicin, Daptomycin, Niraparib, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, Mass., Aug 31, 2020 (GLOBE NEWSWIRE via COMTEX) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) [...]

Published
2020

29. GSK moves further ahead in BCMA with EU okay for Blenrep

Subjects
Bristol-Myers Squibb Co., Niraparib, Monoclonal antibodies, Pomalidomide, Multiple myeloma -- Care and treatment -- Development and progression, Drug approval, Business, international, Law
Abstract

GlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the nod from the European Commission. Blenrep (belantamab mafodotin) becomes the first BCMA-targeted [...]

Published
2020

30. United States : New staff bring significant oncology, immunotherapy and rare disease expertise to Parexels Regulatory & Access Consulting team of 80+ former regulators to help life sciences companies navigate rapidly changing global regulatory landscape

Subjects
Ibrutinib, Niraparib, Immunotherapy, World health, Business, international
Abstract

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, announced the addition of former regulators [...]

Published
2020

33. EU gives AZs Lynparza green light for BRCA-mutated pancreatic cancer

Subjects
Rucaparib, Niraparib, Pancreatic cancer -- Development and progression, Olaparib, Chemotherapy, Business, international, Law, Lynparza (Medication)
Abstract

The approval was based on results from the phase 3 POLO trial of Lynparza (olaparib) in advanced pancreatic cancer patients whose tumours carry BRCA mutations. About 5-7% of metastatic pancreatic [...]

Published
2020

34. Niraparib 100mg

Subjects
Niraparib, Business, international
Abstract

Contract awarded for Niraparib 100mg Date of conclusion of the contract: 02-06-2020 Contract price: 7. 470,00 Deadline: 20 days Place of execution - Country, District, Municipality: Portugal, porto, porto Contractor [...]

Published
2020

35. Onxeo: New AsiDNA e-Poster Now Online at AACR Virtual Meeting 2020

Subjects
Niraparib, General interest, News, opinion and commentary
Abstract

PARIS: Onxeo S.A. has issued the following news release: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ('Onxeo' or 'the Company'), a clinical-stage biotechnology company specializing in the development of innovative [...]

Published
2020

36. New AsiDNA(TM) e-Poster Now Online at AACR Virtual Meeting 2020

Subjects
DNA damage, Niraparib, Carboplatin, Banking, finance and accounting industries, Business
Abstract

PARIS, June 22, Jun 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ('Onxeo' or 'the Company'), a clinical-stage biotechnology company specializing in the development [...]

Published
2020

37. Prostate cancer Pipeline Insights: Emerging Therapies Shifting the Market Landscape Positively

Subjects
Business research -- Reports, Nivolumab -- Reports, Prostate cancer -- Reports, Antineoplastic agents -- Reports, Niraparib, Motor vehicle drivers, Elderly, Medical economics, Abiraterone, Talazoparib, Enzalutamide, Diseases, Rucaparib, Business, Business, international
Abstract

M2 PRESSWIRE-June 11, 2020-: Prostate cancer Pipeline Insights: Emerging Therapies Shifting the Market Landscape Positively (C)1994-2020 M2 COMMUNICATIONS RDATE:10062020 A robust Prostate Cancer pipeline, uptake of potential emerging therapies with [...]

Published
2020

38. Prostate Cancer Market Size Anticipated to Increase with a CAGR of 8.1% in the 7MM for the Study Period 2017-30

Subjects
Denosumab -- Reports, Business research -- Reports, Cabazitaxel -- Reports, Market research -- Reports, Nivolumab -- Reports, Prostate cancer -- Reports, Epidemiology -- Reports, Pharmaceutical industry -- Market research, Antineoplastic agents -- Market research, Niraparib, Fuel industry, Medical economics, Abiraterone, Talazoparib, Enzalutamide, Profits, Rucaparib, Marketing research, General interest, News, opinion and commentary
Abstract

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release: As per DelveInsight's analysis, Prostate Cancer Market Size in the 7MM is anticipated to grow in the coming [...]

Published
2020

39. Prostate Cancer Market Set to Increase at a CAGR of 8.1% for the Study Period 2017-30

Subjects
Denosumab -- Reports -- Forecasts and trends, Business research -- Reports -- Forecasts and trends, Cabazitaxel -- Reports -- Forecasts and trends, Nivolumab -- Reports -- Forecasts and trends, Cancer research -- Reports -- Forecasts and trends, Prostate cancer -- Reports -- Forecasts and trends, Epidemiology -- Reports -- Forecasts and trends, Antineoplastic agents -- Market size -- Reports -- Forecasts and trends, Niraparib, Abiraterone, Talazoparib, Enzalutamide, Profits, Rucaparib, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-June 10, 2020-: Prostate Cancer Market Set to Increase at a CAGR of 8.1% for the Study Period 2017-30 (C)1994-2020 M2 COMMUNICATIONS RDATE:09062020 Prostate Cancer Market Size is Expected [...]

Published
2020

40. Onxeo Announces Approval of the REVocan Study By Regulatory Authorities

Subjects
Cancer treatment, Niraparib, Ovarian cancer -- Care and treatment, DNA, Recurrence (Disease), Ethics, Cancer, DNA damage, DNA repair, Tumors, Biotechnology industries, Business, international, Law
Abstract

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (Onxeo or the Company), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular [...]

Published
2020

41. Onxeo Announces Approval of the REVocan Study by Regulatory Authorities

Subjects
DNA damage, Niraparib, Carboplatin, Ovarian cancer, DNA, Recurrence (Disease), Cancer, DNA repair, Tumors, Biotechnology industries, Banking, finance and accounting industries, Business
Abstract

PARIS, May 29, May 29, 2020 (GLOBE NEWSWIRE via COMTEX) -- The REVocan study aims to evaluate the abrogation by AsiDNA(TM) of tumor resistance to a PARP inhibitor in relapsed [...]

Published
2020

42. Title:provision Of Exclusive Medicines: Niraparib Tosylate Monohydrate

Subjects
Niraparib, Business, international
Abstract

Prior information notice without call for competition: Pharmaceutical products Description of the procurement: Provision of exclusive drugs: niraparib tosylate monohydrate. Value excluding VAT: 151 625.00 EURII.1.6)Information about lots This contract [...]

Published
2020

43. MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO

Subjects
MacroGenics Inc., Niraparib, Monoclonal antibodies, Pharmaceutical industry, Antibodies, Therapeutics, Cancer, Professional associations, Business, international, Law
Abstract

(GlobeNewswire) - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a [...]

Published
2020

44. MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO

Subjects
MacroGenics Inc., Niraparib, Monoclonal antibodies, Pharmaceutical industry, Antibodies, Therapeutics, Cancer, Professional associations, Banking, finance and accounting industries, Business
Abstract

Rockville, MD, May 21, 2020 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics [...]

Published
2020

45. Myriad Receives FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Lynparza in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

Subjects
United States. Food and Drug Administration, Myriad Genetics Inc., Precision medicine, Olaparib, Biotechnology industries, Prostate cancer -- Drug therapy, EDTA, Antineoplastic agents, Genes, Medical personnel, Niraparib, Abiraterone, Biotechnology, DNA repair, Enzalutamide, Novels, Business, international, Law, Lynparza (Medication)
Abstract

(GlobeNewswire) - Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that theU.S. Food and Drug Administration(FDA) approved the BRACAnalysis CDx test for use [...]

Published
2020

46. Myriad Receives FDA Approval of BRACAnalysis CDx(R) as a Companion Diagnostic for Lynparza(R) in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

Subjects
United States. Food and Drug Administration, Myriad Genetics Inc., AstraZeneca PLC, Precision medicine, Olaparib, Biotechnology industries, Prostate cancer -- Drug therapy, EDTA, Antineoplastic agents, Genes, Medical personnel, Niraparib, Abiraterone, Biotechnology, DNA repair, Enzalutamide, Banking, finance and accounting industries, Business, Lynparza (Medication)
Abstract

SALT LAKE CITY, May 20, May 20, 2020 (GLOBE NEWSWIRE via COMTEX) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the [...]

Published
2020

47. Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program

Subjects
Bayer AG, Atezolizumab, Nivolumab, Avelumab, Prostate cancer, Pharmaceutical industry, Cancer metastasis, Antineoplastic agents, Copanlisib, Niraparib, Regorafenib, Cancer, Larotrectinib, Operating systems (Software), Tumors, Setting (Literature), Vincristine, Enzalutamide, General interest, News, opinion and commentary
Abstract

WHIPPANY, N.J.: Bayer has issued the following news release: Data from Bayer's growing oncology portfolio will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, [...]

Published
2020

48. Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program

Subjects
Atezolizumab, Nivolumab, Child health, Avelumab, Cancer metastasis, Antineoplastic agents, Copanlisib, Niraparib, Regorafenib, Cancer, Larotrectinib, Operating systems (Software), Pediatrics, Vincristine, Enzalutamide, Cancer patients, Business, Business, international, Stivarga (Medication), Vitrakvi (Medication), Xofigo (Medication), Aliqopa (Medication), Nubeqa (Medication)
Abstract

* Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating NUBEQA([R])(darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) * Updated efficacy and safety [...]

Published
2020

49. GlaxoSmithKline's Zejula Gets New US Approval In Ovarian Cancer

Subjects
United States. Food and Drug Administration, GlaxoSmithKline PLC, Cancer treatment, Niraparib, Pharmaceutical industry, Drug approval, Ovarian cancer -- Care and treatment, Chemotherapy, Brand names, Women, General interest, News, opinion and commentary, Zejula (Medication)
Abstract

London: GlaxoSmithKline PLC has issued the following press release: GlaxoSmithKline PLC on Thursday said its drug Zejula has been granted US approval as a first-line maintenance treatment for advanced ovarian [...]

Published
2020

50. GlaxoSmithKline PLC - GSK GSK?s Zejula approved in first-line ovarian cancer

Subjects
London Stock Exchange PLC, Securities industry, Niraparib, Drug approval, Ovarian cancer -- Drug therapy, Medical schools, Stock offerings, Stock exchanges, Women, Securities industry, General interest, News, opinion and commentary, Zejula (Medication)
Abstract

London: London Stock Exchange plc has issued the following announcement: FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results